China NT Pharma Group Co Ltd (1011) - Financial and Strategic SWOT Analysis Review

Jun, 2017   |   45  Pages   |   GlobalData   |   Format : PDF

China NT Pharma Group Co Ltd (1011) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

China NT Pharma Group Co Ltd (NT Pharma) is a technology-based pharmaceutical company, which researches, develops, manufactures, and distributes branded and generic pharmaceuticals. The company also promotes and distributes drugs manufactured by third parties. It develops drugs for indications such as cancer; central nervous system disorders; orthopedics; hepatopathy and respiratory disorders. NT Pharmas branded products include Libod and Xi Di Ke for the treatment of various cancers; Miacalcic for bone pain; Shusi, an antipsychotic drug; Zhuoao, a respiratory drug, and Songzhi Wan, a traditional Chinese medicine for the treatment of Hepatitis C. The company operates three production bases for chemical drugs, traditional Chinese medicine and bio-chemical drugs through its subsidiaries, Suzhou First, Jiangsu Biopharma and Changsha Pharma. It operates a research and development facility in Beijing. NT Pharma is headquartered in Wanchai, Hong Kong.

China NT Pharma Group Co Ltd Key Recent Developments

Mar 21,2017: China NT Pharma Group Company: Annual Results Announcement For The Year Ended 31 December 2016
Aug 18,2016: China NT Pharma Group Company: Interim Results Announcement For The Six Months Ended 30 June 2016
May 31,2016: China NT Pharma Group Company Announces Appointment Of Non-executive Director
Jan 29,2016: POSITIVE PROFIT ALERT: China NT Pharma Group Company
Jan 26,2016: NT Pharma will Commence Clinical Research of Lurasidone Hydrochloride

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 - About the Company 5
China NT Pharma Group Co Ltd - Key Facts 5
China NT Pharma Group Co Ltd - Key Employees 6
China NT Pharma Group Co Ltd - Key Employee Biographies 7
China NT Pharma Group Co Ltd - Major Products and Services 8
China NT Pharma Group Co Ltd - History 9
China NT Pharma Group Co Ltd - Company Statement 11
China NT Pharma Group Co Ltd - Locations And Subsidiaries 13
Head Office 13
Other Locations & Subsidiaries 13
Section 2 Company Analysis 15
China NT Pharma Group Co Ltd - Business Description 15
China NT Pharma Group Co Ltd - Corporate Strategy 16
China NT Pharma Group Co Ltd - SWOT Analysis 17
SWOT Analysis - Overview 17
China NT Pharma Group Co Ltd - Strengths 17
China NT Pharma Group Co Ltd - Weaknesses 18
China NT Pharma Group Co Ltd - Opportunities 19
China NT Pharma Group Co Ltd - Threats 20
China NT Pharma Group Co Ltd - Key Competitors 21
Section 3 Company Financial Ratios 22
Financial Ratios - Capital Market Ratios 22
Financial Ratios - Annual Ratios 23
Performance Chart 26
Financial Performance 26
Financial Ratios - Interim Ratios 27
Financial Ratios - Ratio Charts 28
Section 4 Companys Lifesciences Financial Deals and Alliances 29
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 30
China NT Pharma Group Co Ltd, Recent Deals Summary 31
Section 5 Companys Recent Developments 32
Mar 21, 2017: China NT Pharma Group Company: Annual Results Announcement For The Year Ended 31 December 2016 32
Aug 18, 2016: China NT Pharma Group Company: Interim Results Announcement For The Six Months Ended 30 June 2016 33
May 31, 2016: China NT Pharma Group Company Announces Appointment Of Non-executive Director 38
Jan 29, 2016: POSITIVE PROFIT ALERT: China NT Pharma Group Company 39
Jan 26, 2016: NT Pharma will Commence Clinical Research of Lurasidone Hydrochloride 40
Section 6 Appendix 41
Methodology 41
Ratio Definitions 41
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
China NT Pharma Group Co Ltd, Key Facts 5
China NT Pharma Group Co Ltd, Key Employees 6
China NT Pharma Group Co Ltd, Key Employee Biographies 7
China NT Pharma Group Co Ltd, Major Products and Services 8
China NT Pharma Group Co Ltd, History 9
China NT Pharma Group Co Ltd, Subsidiaries 13
China NT Pharma Group Co Ltd, Key Competitors 21
China NT Pharma Group Co Ltd, Ratios based on current share price 22
China NT Pharma Group Co Ltd, Annual Ratios 23
China NT Pharma Group Co Ltd, Annual Ratios (Cont...1) 24
China NT Pharma Group Co Ltd, Annual Ratios (Cont...2) 25
China NT Pharma Group Co Ltd, Interim Ratios 27
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 30
China NT Pharma Group Co Ltd, Recent Deals Summary 31
Currency Codes 41
Capital Market Ratios 41
Equity Ratios 42
Profitability Ratios 42
Cost Ratios 43
Liquidity Ratios 43
Leverage Ratios 44
Efficiency Ratios 44

List of Figures
China NT Pharma Group Co Ltd, Performance Chart (2012 - 2016) 26
China NT Pharma Group Co Ltd, Ratio Charts 28
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 30

China Petrochemicals Report
The China Petrochemicals Report has been researched at source, and features BMI Research's market assessment and independent forecasts for key petrochemicals sub-sectors. The report also analyses the impact of regulatory changes, recent developments and the background macroeconomic outlook and featu
China Oil and Gas Report
BMI View: China's long-term crude oil and liquids output will remain on a firm downtrend as low oil prices slowdown exploration and render certain high-cost mature and unconventional plays uneconomic. Outlook is more positive for natural gas, as the government seeks to increase the share of ga
China Pharmaceuticals and Healthcare Report
BMI View: China will become a leading medical research hub within the Asia Pacific region. This will be largely led by multinational pharmaceutical firms as they seek to tap the large talent pool within the country and develop treatments 'in China, for China'. The local industry, while stil
China Telecommunications Report
BMI View: Operator strategies will continue to chime with the government's directive to drive uptake of wireline broadband and machine-to-machine (M2M) connections. However, this means that even as subscription numbers rise, the prices of basic services will be compressed and operators will derive p
Global and China Lithium Carbonate Industry Report, 2016-2020
Driven by a surge in sales volume of new energy vehicles in China, the upstream material- lithium carbonate was in short supply in the fourth quarter of 2015 with soaring prices. Global lithium carbonate output increased by 12.3% year on year to 202,800 tons in 2015 and is expected to arrive at 244,

Select a Licence type

Custom Research

We are known to provide exact requirements. Try our CUSTOM RESEARCH option and get the exact search result you are searching for.

Contact Us

Postal Address:
808, Real Tech Park, 8th Floor, Sector - 30A, Vashi, Navi Mumbai - 400703 , INDIA .
Telephone: +91 22 27810772, 27810773
Email: info@marketreportsonchina.com
Fax Number: +91 22 27812707

Follow Us On: